|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Boehringer Ingelheim Pharmaceuticals |
|---|---|
| Information provided by: | Boehringer Ingelheim Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT00042068 |
Purpose
A 12-week trial consisting of 5 visits (6 if follow up is needed) to find out how effective and safe three different doses of meloxicam are compared with placebo in Rheumatoid Arthritis. Patient will take one dose of study medication daily.
| Condition | Intervention | Phase |
|---|---|---|
|
Arthritis, Rheumatoid |
Drug: Meloxicam |
Phase III |
| Study Type: | Interventional |
| Study Design: | Randomized, Double-Blind, Placebo Control, Parallel Assignment |
| Official Title: | A Multi-Center, Double-Blind, Randomized, Parallel-Group Trial to Compare the Efficacy and Safety of Three Doses of Meloxicam (7.5, 15, and 22.5 mg) and Placebo in Patients With Rheumatoid Arthritis |
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations
Show 153 Study Locations| Study Chair: | Boehringer Ingelheim Study Coordinator | Boehringer Ingelheim Ltd./Bracknell |
More Information
| Study ID Numbers: | 107.258 |
| Study First Received: | July 22, 2002 |
| Last Updated: | November 25, 2008 |
| ClinicalTrials.gov Identifier: | NCT00042068 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Anti-Inflammatory Agents Autoimmune Diseases Joint Diseases Cyclooxygenase Inhibitors Meloxicam Arthritis, Rheumatoid Rheumatic Diseases Musculoskeletal Diseases |
Analgesics, Non-Narcotic Arthritis Connective Tissue Diseases Anti-Inflammatory Agents, Non-Steroidal Analgesics Peripheral Nervous System Agents Antirheumatic Agents |
|
Anti-Inflammatory Agents Autoimmune Diseases Molecular Mechanisms of Pharmacological Action Immune System Diseases Joint Diseases Cyclooxygenase Inhibitors Physiological Effects of Drugs Meloxicam Arthritis, Rheumatoid Enzyme Inhibitors Rheumatic Diseases Pharmacologic Actions |
Musculoskeletal Diseases Analgesics, Non-Narcotic Sensory System Agents Therapeutic Uses Arthritis Connective Tissue Diseases Anti-Inflammatory Agents, Non-Steroidal Peripheral Nervous System Agents Analgesics Antirheumatic Agents Central Nervous System Agents |